Fig. 2
From: Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors
Gene signature-based approach to predict the outcome of anticancer drug treatment. A The cell line MCF7 and dasatinib and B the cell line A375 and ruxolitinib. Each dot represents a gene whose differential expression in the disease state is on the abscissa and drug-perturbed differential expression is on the ordinate. Differential expression values are computed as the moderated Z-score (modZ) weighted averages of replicated level-5 gene signatures. Those genes having disease associations with breast adenocarcinoma in A and skin melanoma in B are shown as larger circles colored according to the scale on the right. Each plot is divided into quadrants, which are labeled I-IV in A